Immuneering Corporation IMRX
4.27
(0.07)
(1.61%)
as of 25 Sep
- Market cap
- $280.8M
- P/E
- 0.0×
Follow IMRX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (52.15%) | (43.84%) | (43.12%) | (43.75%) |
+8 more TTM periods Free account |
|
| (47.31%) | (41.01%) | (39.36%) | (40.37%) | ||
ROIC |
(97.14%) | (74.29%) | (81.29%) | (9,705.65%) | |
Return on Tangible Assets |
(37.99%) | (34.59%) | (33.53%) | (28.35%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.88) | (0.77) | (1.03) | (1.26) | |
Free Cash Flow |
(56.99) | (49.91) | (45.49) | (50.04) | |
Capital Expenditures |
(0.24) | (0.21) | (0.14) | (0.03) | |
| Other line items | |||||
Cash ROIC |
(16.66%) | (13.68%) | (11.59%) | (10.98%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.99 | 0.91 | 0.81 | 0.80 | |
Depreciation/Fixed assets |
(0.49) | 0.15 | 0.58 | 0.72 | |
Capex/Depreciation |
0.56 | (1.49) | (0.26) | (0.04) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.88) | (0.77) | (1.03) | (1.26) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates